Press releases

Chordate Medical's Caroline Lundgren Brandberg, non-executive Director and main owner, will participate in the Fearless investor conference hosted...
Chordate Medical Holding AB (publ) ("Chordate") has entered into an agreement for liquidity provision with Lago Kapital ("Lago"). According...
The shareholders in Chordate Medical Holding AB (publ), 556962-6319, are hereby given notice of the annual general meeting to be held on Wednesday 15 May...
Chordate Medical Holding AB (Publ) has today published its annual report for 2023. The annual report is available on Chordate's website www.chordate.com...
Yesterday, March 25th, Chordate's CEO Anders Weilandt presented the company's financial report for 2023 on Finwire TV. He also answered questions...
Summary of the period October–December 2023 Summary of the period January–December 2023 COMMENTS FROM CEO ANDERS WEILANDT Breakthrough in several...
Chordate Medical Holding (publ) is releasing its year-end report for 2023 on Friday, March 22nd, at 08:30. On Monday, March 25th, at 11:00, the company...
A new Italian scientific case report, from a team at Campus Bio-Medico in Rome, detailing the Chordate treatment method Ozilia, reports on a 60-year-old...
Chordate Medical's CEO, Anders Weilandt, will present Ozilia at Swiss Nordic Bio in Zurich on March 7th. Swiss Nordic Bio is a high-level partnering...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG...

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact